Dr. Cabanellas achieves cure with a 72% survival rate in patients with anaplastic carcinoma

The specialist highlights the scope of findings in diagnosis and treatment.

Dr. Maria Cabanellas, MD, an endocrinologist at the University of Texas MD Anderson Cancer Center. Photo: Journal of Medicine and Public Health.

In an exclusive interview with the Journal of Medicine and Public Health, Dr. Maria Cabanellas, an endocrinologist at the University of Texas MD Anderson Cancer Center, revealed the impact of her research on anaplastic carcinoma.

In principle, the endocrine oncologist reported that this type of cancer is caused by thyroid cancer that has been around for a long time, “As the days go by, the tumors start to acquire new mutations and by accumulating more mutations, they become more aggressive, an end result , cancer Al-Kashmi”.

Related news

Making hidradenitis visible: the first meeting for patients and health professionals

The specialist noted that between the past five to ten years, more people with this type of cancer were discovered, due to an increase in screening tests also due to the search for answers as to why the tumor is operating so strongly.

This type of cancer mainly affects adult patients But, Cabanillas noted, they also found patients between the ages of 40 and 45 with these tumors.

start investigations

The meeting was one of the highlights of Dr. Maria Cabanellas Sick who have traveled from Italy in search of assistance because of your cancer anaplastic that had already spread, “We actually had nothing to offer for treatment at that time -2012, we could only treat it with already licensed chemotherapy for the head and neck.”

He explained that at that time the team from the University of Texas MD Anderson Cancer Center began looking for ways to meet and care for more patients with this condition with the aim of obtaining information that would serve as a starting point for better outcomes in diagnosis and treatment.

He pointed out that in 2013 he asked his colleagues to send The patients with anaplastic carcinoma to his office,” but I realized I couldn’t do it alone, so in 2014 a multidisciplinary group came together to see The patients With attention between 5 and 7 days once they contact us.”

“Providing them with a quick appointment helped increase and improve care. We must understand that anaphylaxis is not just one, but there are different types of cancers that affect the thyroid gland and this type of cancer becomes.”

One aspect that we’ve found is that they’re not all treated the same way, they’re different types of cancer, “because we’re starting to see mutations in the cancers in all of them. That is, we saw Sick with anaplastic carcinoma With Halimi by his side. This is how we began to understand that it is not a type of cancer, and that is why not everyone can be cured The patients same”.

search input

The specialist explained that the second phase of the clinical trial that they conducted with patients around the world measured the effects of only the two drugs approved for them cancer anaplastic “but after 14 months of halving The patients They stopped responding to treatment and died.

Noting this setback, the researchers chose to include immunotherapy for both drugs, and the results were favorable The patients.

“What we did was add immunotherapy with other drugs, Braf inhibitors, Med inhibitor, and the third which is immunotherapy, and using that combination we found that at 24 months, 72% of The patients They are alive. So we’re looking at how to change treatment from just giving two to three drugs.

Another study that is being done, according to Dr. Cabanillas, concerns the tumor itself, “where we saw that it could not be removed, because when Sick Anaphylactic is diagnosed and the tumor is very large and what we have done is treat the patient before surgery and follow up treatment after surgery or give him radiation. So we are studying whether this surgery is beneficial The patients“.

He added that there comes a point when the patient cannot breathe due to the size of the tumor, and there comes a point in treatment where the progress of drugs stops and the tumor accumulates new mutations.

“The drug no longer works on new mutations, so the patient doesn’t have many options, so before that happens we want to remove the tumor from the patient,” he explained.

Regarding goals and challenges, Dr. Cabanellas noted that only 40 percent of The patients with anaplastic carcinoma They have a BRAF mutation and are the beneficiaries of this treatment, but there are also patients who have more complex mutations in treatment.

“We give them a combined treatment and not all of them respond, so we try to tell the difference between them The patients Which respond well to immunotherapy and some do not, through histology. I hope to publish this research this year, but we still have a lot of work to do The patients which do not contain a mutation in BRAF,” he explained.

People realize that understanding this cancer at the molecular level is very important, and this message has already reached Puerto Rico and Latin America. “In the latter case, the biggest challenge is getting access to treatments, but little by little with the publication of trials and professional guidelines, I think it has improved a lot, but it is still a problem for the poorest countries.”

Watch the full programme: